Background/Aims: Notch signaling pathway regulates cancer cell growth. RBPJ is a key transcription factor downstream of Notch receptor activation, whereas the role of RBPJ in carcinogenesis of prostate cancer is ill-defined. Methods: Here, we evaluated the effects of RBPJ inhibition on the growth of prostate cancer cells. We knocked down RBPJ in prostate cancer cells by a short hairpin interfering RNA (shRNA). We measured cell growth by an MTT assay. We analyzed the levels of cell-cycle-associated proteins by Western blot. Results: We found that shRNA for RBPJ efficiently inhibited RBPJ expression in prostate cancer cells, resulting in a significant decrease in the cell growth. Further, RBPJ-mediated cell-growth inhibition appeared to be re...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Aberrant Notch activity is oncogenic in several malignancies, but it is unclear how expression or fu...
The androgen receptor (AR) is a critical effector of prostate cancer development and progression. An...
The Notch signaling pathway, which converges on RBPJ, is deregulated in a number of malignancies. Fo...
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of pros...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
The Notch pathway regulates a broad spectrum of cell fate decisions and differentiation processes du...
3 Relaxin (RLN) is a small peptide hormone expressed in several cancers of reproductive and endocrin...
Androgen receptor is a primary transcription factor involved in the proliferation of prostate cancer...
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transd...
Androgen receptor is a primary transcription factor involved in the proliferation of prostate cancer...
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transd...
Prostate cancer is the second most common cancer diagnosed for men in the U.S. Treatments for Castra...
Current hormonal therapies for prostate cancer are effective initially, but inevitably tumours progr...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Aberrant Notch activity is oncogenic in several malignancies, but it is unclear how expression or fu...
The androgen receptor (AR) is a critical effector of prostate cancer development and progression. An...
The Notch signaling pathway, which converges on RBPJ, is deregulated in a number of malignancies. Fo...
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of pros...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
The Notch pathway regulates a broad spectrum of cell fate decisions and differentiation processes du...
3 Relaxin (RLN) is a small peptide hormone expressed in several cancers of reproductive and endocrin...
Androgen receptor is a primary transcription factor involved in the proliferation of prostate cancer...
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transd...
Androgen receptor is a primary transcription factor involved in the proliferation of prostate cancer...
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transd...
Prostate cancer is the second most common cancer diagnosed for men in the U.S. Treatments for Castra...
Current hormonal therapies for prostate cancer are effective initially, but inevitably tumours progr...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Aberrant Notch activity is oncogenic in several malignancies, but it is unclear how expression or fu...
The androgen receptor (AR) is a critical effector of prostate cancer development and progression. An...